Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
NYU Langone Health
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01981759CT.gov D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Delusional Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dcs (this asset) | NYU Langone Health | Approved | BB · 67 |
| Agomelatine | Central Institute of Mental Health, Mannheim | P4 | BB |
| Ziprasidone | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | P4 | BB |
| Rituximab | Uppsala University Hospital | P2 | CCC |
| Risperidone | Centre for Addiction and Mental Health | N/A | D |
| Olanzapine | Centre for Addiction and Mental Health | N/A | D |
| Cogentin | Centre for Addiction and Mental Health | N/A | D |
Other indications for Dcs
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Disorder | — | P4 | BB · 69 |
| Schizophrenia | — | P4 | BB · 68 |
| Schizoaffective Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dcs in Delusional Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dcs-delusional-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →